#ASH18: Celgene offers up a stellar complete response rate for JCAR017. Will anyone notice?
It’s getting harder and harder to make a splash with personalized CAR-Ts for leukemia and lymphoma, but Celgene is giving it a go today at ASH.
Their CAR-T team at Juno — now a subsidiary of Celgene’s — offered up a stellar round of objective responses rates for JCAR017 in their Phase I/II study for a small group of high-risk patients suffering from drug resistant chronic lymphocytic leukemia and small lymphocytic lymphoma.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 105,400+ biopharma pros reading Endpoints daily — and it's free.